開示日時：2022/04/25 08:30:00
損益
| 決算期 | 売上高 | 営業益 | 経常益 | EPS |
| 2018.12 | 31,800 | -241,900 | -241,900 | -25.98 |
| 2019.12 | 131,000 | -176,200 | -176,200 | -17.75 |
| 2020.12 | 45,400 | -411,600 | -411,600 | -35.16 |
※金額の単位は［万円］
株価
| 前日終値 | 50日平均 | 200日平均 | 実績PER | 予想PER |
| 104.0 | 105.72 | 128.965 | – | – |
※金額の単位は［円］
キャッシュフロー
| 決算期 | フリーCF | 営業CF |
| 2018.12 | -258,000 | -232,300 |
| 2019.12 | -156,000 | -82,800 |
| 2020.12 | -296,000 | -278,900 |
※金額の単位は［万円］
▼テキスト箇所の抽出
To: All Concerned Parties April 25, 2022 Company Name: Solasia Pharma K.K. Representative: Yoshihiro Arai, President & CEO (Code number: Contact: Tel: URL: 4597, TSE Growth Section) Toshio Miyashita, CFO, Director 81-3-5843-8046 https://solasia.co.jp/en/ Solasia’s Partner, Isofol announced start of study data analysis of SP-05 (arfolitixorin) phase III AGENT study Isofol Medical AB (publ) (STO: ISOFOL), Solasia’s partner announced that the start of data analysis of the multi-center, global Phase III AGENT Study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC). For more information, please refer to the Isofol´s website. https://isofolmedical.com/ ### 1
